142 related articles for article (PubMed ID: 32321250)
21. APOBEC3H structure reveals an unusual mechanism of interaction with duplex RNA.
Bohn JA; Thummar K; York A; Raymond A; Brown WC; Bieniasz PD; Hatziioannou T; Smith JL
Nat Commun; 2017 Oct; 8(1):1021. PubMed ID: 29044109
[TBL] [Abstract][Full Text] [Related]
22. Structural basis of chimpanzee APOBEC3H dimerization stabilized by double-stranded RNA.
Matsuoka T; Nagae T; Ode H; Awazu H; Kurosawa T; Hamano A; Matsuoka K; Hachiya A; Imahashi M; Yokomaku Y; Watanabe N; Iwatani Y
Nucleic Acids Res; 2018 Nov; 46(19):10368-10379. PubMed ID: 30060196
[TBL] [Abstract][Full Text] [Related]
23. The Structural Interface between HIV-1 Vif and Human APOBEC3H.
Ooms M; Letko M; Simon V
J Virol; 2017 Mar; 91(5):. PubMed ID: 28031368
[TBL] [Abstract][Full Text] [Related]
24. Mapping Region of Human Restriction Factor APOBEC3H Critical for Interaction with HIV-1 Vif.
Nakashima M; Tsuzuki S; Awazu H; Hamano A; Okada A; Ode H; Maejima M; Hachiya A; Yokomaku Y; Watanabe N; Akari H; Iwatani Y
J Mol Biol; 2017 Apr; 429(8):1262-1276. PubMed ID: 28336404
[TBL] [Abstract][Full Text] [Related]
25. Structural basis of substrate specificity in human cytidine deaminase family APOBEC3s.
Hou S; Lee JM; Myint W; Matsuo H; Kurt Yilmaz N; Schiffer CA
J Biol Chem; 2021 Aug; 297(2):100909. PubMed ID: 34171358
[TBL] [Abstract][Full Text] [Related]
26. Polymorphisms and splice variants influence the antiretroviral activity of human APOBEC3H.
Harari A; Ooms M; Mulder LC; Simon V
J Virol; 2009 Jan; 83(1):295-303. PubMed ID: 18945781
[TBL] [Abstract][Full Text] [Related]
27. APOBEC3H polymorphisms associated with the susceptibility to HIV-1 infection and AIDS progression in Japanese.
Sakurai D; Iwatani Y; Ohtani H; Naruse TK; Terunuma H; Sugiura W; Kimura A
Immunogenetics; 2015 Apr; 67(4):253-7. PubMed ID: 25721876
[TBL] [Abstract][Full Text] [Related]
28. Sole copy of Z2-type human cytidine deaminase APOBEC3H has inhibitory activity against retrotransposons and HIV-1.
Tan L; Sarkis PT; Wang T; Tian C; Yu XF
FASEB J; 2009 Jan; 23(1):279-87. PubMed ID: 18827027
[TBL] [Abstract][Full Text] [Related]
29. Polymorphism in human APOBEC3H affects a phenotype dominant for subcellular localization and antiviral activity.
Li MM; Emerman M
J Virol; 2011 Aug; 85(16):8197-207. PubMed ID: 21653666
[TBL] [Abstract][Full Text] [Related]
30. Mechanism for APOBEC3G catalytic exclusion of RNA and non-substrate DNA.
Solomon WC; Myint W; Hou S; Kanai T; Tripathi R; Kurt Yilmaz N; Schiffer CA; Matsuo H
Nucleic Acids Res; 2019 Aug; 47(14):7676-7689. PubMed ID: 31424549
[TBL] [Abstract][Full Text] [Related]
31. Crystal Structure of a Soluble APOBEC3G Variant Suggests ssDNA to Bind in a Channel that Extends between the Two Domains.
Maiti A; Myint W; Delviks-Frankenberry KA; Hou S; Kanai T; Balachandran V; Sierra Rodriguez C; Tripathi R; Kurt Yilmaz N; Pathak VK; Schiffer CA; Matsuo H
J Mol Biol; 2020 Nov; 432(23):6042-6060. PubMed ID: 33098858
[TBL] [Abstract][Full Text] [Related]
32. APOBEC3H Subcellular Localization Determinants Define Zipcode for Targeting HIV-1 for Restriction.
Salamango DJ; Becker JT; McCann JL; Cheng AZ; Demir Ö; Amaro RE; Brown WL; Shaban NM; Harris RS
Mol Cell Biol; 2018 Dec; 38(23):. PubMed ID: 30224517
[TBL] [Abstract][Full Text] [Related]
33. HIV-1 competition experiments in humanized mice show that APOBEC3H imposes selective pressure and promotes virus adaptation.
Nakano Y; Misawa N; Juarez-Fernandez G; Moriwaki M; Nakaoka S; Funo T; Yamada E; Soper A; Yoshikawa R; Ebrahimi D; Tachiki Y; Iwami S; Harris RS; Koyanagi Y; Sato K
PLoS Pathog; 2017 May; 13(5):e1006348. PubMed ID: 28475648
[TBL] [Abstract][Full Text] [Related]
34. Crystal structure of APOBEC3A bound to single-stranded DNA reveals structural basis for cytidine deamination and specificity.
Kouno T; Silvas TV; Hilbert BJ; Shandilya SMD; Bohn MF; Kelch BA; Royer WE; Somasundaran M; Kurt Yilmaz N; Matsuo H; Schiffer CA
Nat Commun; 2017 Apr; 8():15024. PubMed ID: 28452355
[TBL] [Abstract][Full Text] [Related]
35. APOBEC3H haplotypes and HIV-1 pro-viral vif DNA sequence diversity in early untreated human immunodeficiency virus-1 infection.
Gourraud PA; Karaouni A; Woo JM; Schmidt T; Oksenberg JR; Hecht FM; Liegler TJ; Barbour JD
Hum Immunol; 2011 Mar; 72(3):207-12. PubMed ID: 21167246
[TBL] [Abstract][Full Text] [Related]
36. Differential Activity of APOBEC3F, APOBEC3G, and APOBEC3H in the Restriction of HIV-2.
Meissner ME; Willkomm NA; Lucas J; Arndt WG; Aitken SF; Julik EJ; Baliga S; Mansky LM
J Mol Biol; 2022 Jan; 434(2):167355. PubMed ID: 34774569
[TBL] [Abstract][Full Text] [Related]
37. DNA mutagenic activity and capacity for HIV-1 restriction of the cytidine deaminase APOBEC3G depend on whether DNA or RNA binds to tyrosine 315.
Polevoda B; Joseph R; Friedman AE; Bennett RP; Greiner R; De Zoysa T; Stewart RA; Smith HC
J Biol Chem; 2017 May; 292(21):8642-8656. PubMed ID: 28381554
[TBL] [Abstract][Full Text] [Related]
38. APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.
Krisko JF; Begum N; Baker CE; Foster JL; Garcia JV
J Virol; 2016 May; 90(9):4681-4695. PubMed ID: 26912618
[TBL] [Abstract][Full Text] [Related]
39. Structural basis of HIV-1 Vif-mediated E3 ligase targeting of host APOBEC3H.
Ito F; Alvarez-Cabrera AL; Kim K; Zhou ZH; Chen XS
Nat Commun; 2023 Aug; 14(1):5241. PubMed ID: 37640699
[TBL] [Abstract][Full Text] [Related]
40. Evolutionarily conserved pressure for the existence of distinct G2/M cell cycle arrest and A3H inactivation functions in HIV-1 Vif.
Zhao K; Du J; Rui Y; Zheng W; Kang J; Hou J; Wang K; Zhang W; Simon VA; Yu XF
Cell Cycle; 2015; 14(6):838-47. PubMed ID: 25590520
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
